VC-backed start-ups may need to think and act differently, perhaps more judiciously, about effective governance than more established firms. The stakes for start-ups are higher and the environment for failure is less forgiving than for established enterprises. In addition to their oversight role, directors at start-ups should be considered strategic assets. Developing a relation-based model built on a board/CEO partnership can increase the odds for success.
By Joe Mandato
In an interview in Fortune last summer, Intel Corp. chairman Andy Grove explained how he had shifted the primary mission...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Recent moves in the industry include C-suite changes at Abvance Therapeutics, plus Galapagos gets new chief financial officer from Horizon Therapeutics.
The gene therapy developer appointed a new president, chief medical officer and chief of staff following the closing of its acquisition by private equity firms Carlysle and SK Capital.
From a letter of intent with BIRAC sealed at BIO 2025 to supporting Immuneel’s CAR-T efforts and a study for point-of-care manufactured anti-CD19 CAR-T cell therapy, Miltenyi Biotec is moving on multiple fronts in India. The German group also expects to advance its own CAR-T candidates.
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Multi-blockbuster falls short in a giant cell arteritis study.
Recent moves in the industry include C-suite changes at Abvance Therapeutics, plus Galapagos gets new chief financial officer from Horizon Therapeutics.
Once hailed as a potential game changer, OG-6219 gets the axe after failing in a Phase II endometriosis-related pain trial.
